Abstract Library

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#4358 Patients with neuroendocrine tumour after surgical treatment and therapy with somatostatin analogues: Comparison of body mass index (BMI)

Introduction: Neuroendocrine tumours (NET) are heterogeneous neoplasms, commonly arising in the gastroenteropancreatic tract (GEP-NET) or bronchopulmonary (L-NET). Surgery is the first line treatment, when possible, while somatostatin analogues (SSA) are the main medical therapy. However, the impact of these therapies on anthropometric indices has not been fully explored.

Conference:

Presenting Author:

Authors: Di Iasi G, Benevento E, Cannavale G, Di Nola M, Liccardi A,

Keywords: BMI, NET, SSA, SURGERY, WEIGHT LOSS, GEP-NET, LUNG NET, WAIST CIRCUMFERENCE, HIP CIRCUMFERENCE,

#4333 Clinical efficacy of peptide receptor radionuclide therapy with radiolabelled somatostatin analogues (PRRT) of metastatic neuroendocrine tumours (NETs) – A single-centre cohort study

Introduction: PRRT is indicated for disease progression in patients with disseminated or unresectable NETs, especially those originating from the midgut. Up to date clinical trials have proven the efficacy of PRRT in gastrointestinal NETs, while data on other localisations are limited.

Conference:

Presenting Author:

Authors: Hamm M, Kropinska A, Handkiewicz-Junak D, Ledwon A, Paliczka-Cieslik E,

Keywords: PRRT, NET, gastrointestinal, pancreatic, bronchopulmonary, FPI,

#4214 Splenic metastases in the course of neuroendocrine tumors – Are they really that uncommon?

Introduction: Splenic metastases are described as exceptional in the literature. Their frequency is low regardless of the type of neoplasm. In the course of neuroendocrine tumors (NETs), spleen involvement seems infrequent too. There is only a limited number of case reports of such presentation.

Conference:

Presenting Author:

Authors: Maciejewski A, Komarnicki P, Wietrzyk D, Musiałkiewicz J, Woliński K,

Keywords: NETs, metastases, spleen, clinical course,